Image by National Cancer Institute
 

DRIVING TARGETED PROTEIN DEGRADATION BY LEVERAGING DIFFERENTIABLE DESIGN STRATEGIES AND MOLECULAR DYNAMICS TO PREDICT, OPTIMIZE, AND DELIVER BETTER THERAPEUTICS

Our mission is to bring about a revolution in the entire process of inventing protein degradation therapeutics, replacing the sequential, artisanal approach that currently dominates the industry, with an efficient, integrated, AI-first, physics-based learning system that is suited to the complexity of protein degradation discovery. We are driven to codify and systematize drug discovery, to move away from this sequential approach, and scale the creation of precision-engineered protein degraders.

Laboratory Scientist
 

OUR AUTODX PLATFORM

We utilize our proprietary AI-driven AutoDx platform to discover protein degraders for genetically defined disease drivers

Protein degraders represent a novel class of small molecules designed to act on a diverse array of diseases. We have developed a proprietary framework that combines our understanding of medicinal chemistry, molecular simulation, and statistical inference to design degraders that stabilize a ternary complex and elicit a favorable therapeutic response. 


Currently TPD discovery is limited by throughput and complexity. To address this, our AutoDx platform precision engineers end-to-end design strategies and molecular dynamics to drive efficient and effective TPD discovery including:

Biological Discovery: Proprietary datasets processed and curated to identify TPD targets and match with appropriate E3 ligase based on tissue specific expression, distribution, and intracellular localization

Multiobjective Design: Active learning focused on multiparameter optimization of protein degraders using generative modeling and molecular dynamics

Translational Studies: AI-driven quantitative systems pharmacology models for safety, efficacy, biomarker stratification, and patient selection to drive success in clinical development

Embryonic Stem Cells